Johnson & Johnson Raises 2026 Sales Outlook to $100.3–101.3 Billion After 10% Q1 Revenue Jump
Johnson & Johnson reported adjusted Q1 EPS of $2.70, topping estimates, and raised its 2026 sales guidance to $100.3–101.3 billion with adjusted EPS of $11.45–11.65. Q1 revenue climbed nearly 10% as new therapies including Tremfya, Caplyta and Icotyde gained traction and US manufacturing saw $12 billion invested.
1. Q1 Performance and Outlook
Johnson & Johnson delivered adjusted first-quarter earnings of $2.70 per share, one cent above estimates, while total sales rose nearly 10% year-over-year. Management raised full-year 2026 guidance to $100.3–101.3 billion in sales and $11.45–11.65 in adjusted EPS, reflecting confidence in underlying growth.
2. Investment in New Therapies and Manufacturing
The company described Q1 as a front-loaded investment phase, channeling spending into newer products such as Tremfya and Caplyta. Early Icotyde adoption reached approximately 1,500 patients, and Johnson & Johnson has deployed $12 billion of a $55 billion US manufacturing commitment to support future output.
3. Portfolio Growth Drivers and Strategic Moves
Growth shifted toward newer therapies as Stelara faced price competition; oncology treatments like Darzalex and the Rybrevant-Lazcluze combination surged, with the latter up 83%. Spravato sales rose over 46%, the medical devices segment grew 7.7%, and a planned orthopedics spin-off could unlock strategic flexibility.